{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"AMG420","nct_id":"NCT03836053","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=amg420-nct03836053. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AMG420","arms":[{"description":"Single Arm Design","label":"AMG 420","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-04-21","type":"ACTUAL"},"conditions":["Relapsed and/or Refractory Multiple Myeloma"],"enrollment":{"count":23,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"AMG 420","otherNames":[],"type":"DRUG"}],"last_update":"2025-09-11","lead_sponsor":"Amgen","official_title":"A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2022-04-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Dose-limiting Toxicities (DLTs)","timeFrame":"Day 1 to Week 4"},{"measure":"Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)","timeFrame":"Up to approximately 3 years"},{"measure":"Number of Participants Who Experienced a Treatment-related TEAE","timeFrame":"Up to approximately 3 years"}],"references":[{"citation":"Rodriguez C, Rodriguez T, Kentos A, Driessen C, Sunami K, Lesokhin AM, Yee AJ, Minella AC, Maraboina R, Upreti VV, Zhou D, Shabooti M, Stieglmaier J, Quach H. BCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study. Leuk Lymphoma. 2025 Nov;66(11):2108-2117. doi: 10.1080/10428194.2025.2528115. Epub 2025 Jul 21.","pmid":"40690374","type":"BACKGROUND"}],"start_date":{"date":"2019-03-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT03836053"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/amg420-nct03836053"}